熱門資訊> 正文

Vera Therapeutics宣布公开募股2亿美元

2025-12-09 05:31

Vera Therapeutics (NVSDAQ:ERA) stated on Monday that it had commenced a public offering to issue and sell $200M of shares, and the underwriters will have a 30-day option to purchase up to an additional 15% of the shares of Class A common stock.
J.P. Morgan, Goldman Sachs & Co. LLC, Evercore ISI, and Cantor are acting as joint book-running managers for the proposed offering.
LifeSci Capital is acting as lead manager for the proposed offering.
The offering is being made pursuant to an automatic shelf registration statement that was filed with the SEC on October 28, 2024, and became effective upon filing.

More on Vera Therapeutics

Vera Therapeutics, Inc. (VERA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Vera Therapeutics: Stock Rises As IgAN Approval Chances Increase - I'm On Sidelines
Vera Therapeutics, Inc. (VERA) Discusses Interim Results of ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy Transcript
Goldman's 48 potential M&A candidates
Seeking Alpha’s Quant Rating on Vera Therapeutics

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。